OncoSolid™ Fallopian Tube Carcinoma Cancer Organoid Model based CAR-T In Vitro Efficacy Assay Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Fallopian Tube Carcinoma Cancer Organoid Models

The transition of fallopian tube epithelial (FTE) cells to cancer cells originated from the TP53 gene mutation. The clonal expansion of the TP53 mutated cells can progress to FTE carcinoma and high-grade serous tubo-ovarian cancer (HGSCs). Genomic analysis of cancer cells demonstrates the various types of genetic abnormalities, including single nucleotide variants, gene deletion, copy number alterations, and gene silencing, which influence downstream gene expression and pathways. Poor response and resistance to current chemotherapy provoke the development of novel effective therapies for tumor treatment.

Creative Biolabs provides a platform for fallopian tube carcinoma cancer organoids with different genotypes for disease modeling and application to CAR therapy development.

Fig.1 Fallopian tube carcinoma cancer organoids establishment and characterization. (Yucer, et al., 2021)

Our Fallopian Tube Carcinoma Cancer Organoid Types

Fallopian Tube Carcinoma Cancer Organoid Types

Culture System

Organoid cultivation from tumor fragments requires some growth factors, such as Wnt3a, RSPO1, N2, B27, epidermal growth factor (EGF), and fibroblast growth factor (FGF).
We provide basal medium supplemented with optimized growth components and differentiation factors for efficient organoids generation.
Our experts have deep knowledge of the function of individual growth factors and combinations of growth factors to regulate stemness and differentiation.

Complete Characterization of Fallopian Tube Carcinoma Cancer Organoids

Related Pathogenic Gene

Reported Abnormal Genes
TP53	BRCA1	BRCA2	Nf1	RAD51
PTEN	EMSY	CCNE1	MYC

Key Features of The Service

Mirror the genomic features of FTE carcinoma;
Organoids can be incubated with immune cells and stromal cells;
Virus vectors and CRISPR/Cas9 techniques are applied to edit organoids;
Well-characterization of established organoids.

Application of Fallopian Tube Carcinoma Cancer Organoids

Tumor Modeling

Explain the correlation between genotype and phenotype
Modeling tumor initiation and progress
Uncovering the combined mutations in carcinogenesis

In Vitro Efficacy Test

Drug sensitivity test
CAR-cell therapy responses test

Related CAR-T Products and Services

The cancer organoids are advanced and easily manipulate models for CAR-T in vitro anti-tumor efficacy evaluations. Creative Biolabs provides the following cancer antigen-related products that could be used in CAR-T construction and examination assays.

Target Antigen	Target Description	CAR-T Products
MUC16	MUC16, also named CA125, is overexpressed in ovarian cancer and is regarded as an attractive target for therapy.	Anti-MUC16 CAR-T

Product Description
CAR IVT Plasmid-mRNA-LNP Products CAR Vector Products CAR Cells CAR Jurkat Cell Products Viral Particle Products CARMA Vector Products CARMA Cell Products CAR Animal Cells

Creative Biolabs is committed to cancer study using multiple advanced technologies and methods, and we provide a system of cancer organoid models to accelerate targeted cell therapy development for solid tumors. Please contact us for further discussion.

Reference

Yucer, N.; et al. Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis. Cell reports. 2021, 37(13): 110146.